Smithkline Beecham Corporation

Glaxosmithkline LLC

Steven Ludbrook

Simon Thomas Barry

Carmel Horgan

David Drysdale Miller

Amino acids 136 to 142 and amino acids 162 to 168 of human osteopontin constitute two sites at which osteopontin interacts with &#x3b1;4 integrins. Products capable of disrupting those interactions are useful in therapy, particularly in the treatment of inflammatory diseases.

Method of screening for inhibitors of osteopontin

Amino acids (136 to 142) and amino acids (162 to 168) of human osteopontin constitute two sites at which osteopontin interacts with &#x3b1;4 integrins. Products capable of disrupting those interactions are useful in therapy, particularly in the treatment of inflammatory diseases.

A method for the identification of a modulator of the interaction between latency asssociated peptide (LAP) of transforming growth factor &#x3b2;1 (TGF-&#x3b2;1) and the integrin ab, which method comprises: (a) providing, as a first component, LAP-&#x3b2;1 or a functional variant thereof (b) providing, as a second component, integrin abor a functional variant thereof (c) contacting the two components with a test product under conditions that, in the absence of the test product, would permit the two components to interact; and (d) determining whether the test product is capable of modulating the interaction between the first and second components, thereby to determine whether the test product is a modulator of the interaction between LAP-&#x3b2;1 and integrin ab.

Growing community of inventors

Stevenage, United Kingdom

Steven Ludbrook